65515-28-8

Basic information

• Product Name: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&
• Synonyms: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&;methyl 2,6-dichloronicotinate (en);2,6-two chloroMethyl nicotinate;Methyl2,6-dichloronicotinate,97%;2,6-Dichloropyridine-3-carboxylic acid methyl ester;Methyl 2,6-dichloropyridin-3-carboxylate;3-Pyridinecarboxylic acid, 2,6-dichloro-, methyl ester
• CAS NO: 65515-28-8
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.027
• Mol File: 65515-28-8.mol
• Article Data: 33

Chemical Properties

• Melting Point: 56-60 °C(lit.)
• Boiling Point: 270.517 °C at 760 mmHg
• Flash Point: 117.405 °C
• Appearance: /
• Density: 1.426 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -4.55±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(65515-28-8)
• EPA Substance Registry System: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(65515-28-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 65515-28-8(Hazardous Substances Data)

Usage

Uses

Replacement of chlorides with fluorides using anhydrous nucleophilic fluoride salts generated from potassium fluoride and an arene transfer agent.

InChI:InChI=1/C7H5Cl2NO2/c1-12-7(11)4-2-3-5(8)10-6(4)9/h2-3H,1H3

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 77-78-1 dimethyl sulfate 
• 67-56-1 methanol 
• 68-12-2 N,N-dimethyl-formamide 
• 186581-53-3 diazomethane 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 58584-83-1 2,6-dichloronicotinoyl chloride 

Downstream Products

• 1005756-36-4 methyl 6-chloro-2-(3-fluorophenethylamino)nicotinate 
• 65515-26-6 methyl 2,6-dimethoxypyridine-3-carboxylate 
• 65515-32-4 methyl 6-chloro-2-methoxypyridine-3-carboxylate 
• 275384-67-3 2-chloro-6-phenylpyridine-3-carboxylic acid methyl ester 
• 1312697-84-9 5-[5-(3,5-bistrifluoromethylphenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-imidazo[1,2-a]pyridine-8-carboxylic acid 
• 1312697-70-3 2-amino-6-[5-(3,5-bistrifluoromethyl-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-nicotinic acid methyl ester 
• 1312697-71-4 5-[5-(3,5-bistrifluoromethylphenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-imidazo[1,2-a]pyridine-8-carboxylic acid methyl ester 
• 1312697-69-0 6-[5-(3,5-bistrifluoromethyl-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-2-bis(tert-butoxycarbonyl)amino-nicotinic acid methyl ester 
• 149539-81-1 methyl 6-amino-2-methoxypyridine-3-carboxylate 
• 680208-55-3 2-methoxy-6-(4-methoxy-benzylamino)-nicotinic acid methyl ester 
• 680208-62-2 6-methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 680208-61-1 6-methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

A scalable and safe continuous flow procedure for in-line generation of diazomethane and its precursor MNU

Diazomethane is a valuable C1-building block for organic synthesis. Due to its intrinsic reactivity and instability, handling of this reagent is associated with serious safety hazards. Herein we present a simple and robust continuous flow process, allowing a safe and on-demand generation of diazomethane with a productivity of 95-117 mmol h-1. The developed two-step process starts from non-hazardous N-methylurea, and generates and consumes N-methyl-N-nitrosourea (MNU) and diazomethane, thus enabling a safe and convenient scale-up to a multi-gram scale in a conventional synthesis laboratory.